Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 901 to 925 of 1150 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
691 increased acute inflammatory response (GO:0002526) Cytokine (FMA:84050) None
692 increased cell activation involved in immune response (GO:0002263) leukocyte (CL:0000738) 1494: Leukocyte recruitment/activation
693 increased cell activation involved in immune response (GO:0002263) tissue-resident macrophage (CL:0000864) None
694 increased cell activation involved in immune response (GO:0002263) 1492: Tissue resident cell activation
695 increased acute inflammatory response (GO:0002526) 1493: Increased Pro-inflammatory mediators
699 increased regulation of protein modification process (GO:0031399) histone (CHEBI:15358) 1503: Histone acetylation, increase
700 increased positive regulation of gene expression (GO:0010628) cyclin-dependent kinase inhibitor (PR:000000014) 1504: p21 (CDKN1A) expression, increase
702 increased increased apoptosis (MP:0006042) apoptosis fated cell (CL:0000445) None
709 increased endocytosis (GO:0006897) lysosomal membrane (GO:0005765) 1539: Endocytotic lysosomal uptake
714 increased cellular response to oxidative stress (GO:0034599) 1394: Induction, persistent proliferation/sustained proliferation
715 increased macrophage activation involved in immune response (GO:0002281) macrophage (CL:0000235) 1394: Induction, persistent proliferation/sustained proliferation
719 increased hypoxia-inducible factor-1alpha signaling pathway (GO:0097411) None
721 increased DNA molecule region (FMA:84119) None
723 increased Testicular atrophy (HP:0000029) Testis (FMA:7210) 1506: Testicular atrophy
724 increased G-protein coupled acetylcholine receptor binding (GO:0031789) muscarinic acetylcholine receptor (PR:000001488) 1602: Increased Muscarinic Acetylcholine Receptors
725 increased Wnt protein secretion (GO:0061355) protein-serine O-palmitoleoyltransferase porcupine (PR:000030936) 1754: Increase, porcupine-induced Wnt secretion and Wnt signaling activation
728 increased gene expression (GO:0010467) teratocarcinoma-derived growth factor 1 (PR:000030513) None
740 increased male gonad development (GO:0008584) immature gonad (UBERON:2005272) 1790: Increased, Differentiation to Testis
741 increased male sex differentiation (GO:0046661) population of organisms (PCO:0000001) 1791: Increased, Male Biased Sex Ratio
755 increased viral RNA genome replication (GO:0039694) None
756 increased viral RNA genome replication (GO:0039694) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
757 increased positive stranded viral RNA replication (GO:0039690) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
758 increased regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122) 1172: Increased activation, Nuclear factor kappa B (NF-kB)
759 increased Venous thrombosis (HP:0004936) platelet (CL:0000233) 1846: Thrombosis and Disseminated Intravascular Coagulation
760 increased viral RNA genome packaging (GO:0019074) None